Biotech entity
gene-therapy is the sole category represented across all 1 tracked stories. Jack Kaye is most often covered alongside AMT-130, which appears in 1 of these 1 story. The tracked stories average 3 original sources each. Jack Kaye appears in 1 tracked Biotech story from August 5, 2026.
Last mentioned: Aug 5, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
gene-therapy is the sole category represented across all 1 tracked stories. Jack Kaye is most often covered alongside AMT-130, which appears in 1 of these 1 story. The tracked stories average 3 original sources each. Jack Kaye appears in 1 tracked Biotech story from August 5, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 6 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Jack Kaye. Shared-story counts are live from our verified record — not editorial picks.
SEC filings and market close
Stock closes at $27.57, up 2.8%; SEC Form 4 filings reveal the three insider transactions.
Insider sales executed
Directors Kaye, Balachandran, and Meek each sell 1,993 shares at $27.06.
Q1 2026 earnings
uniQure reports revenue of $3.56M (miss) and EPS of -$0.85 (beat by $0.03); net margin remains deeply negative.
RBC upgrade
RBC Capital upgrades uniQure from sector perform to outperform, raising price target from $11 to $35.
Three uniQure directors each offloaded 1,993 shares at $27.06, pocketing a combined $162K. The gene therapy company’s stock trades above key moving averages after an RBC upgrade, but sales hint at insider caution amid heavy cash burn.
Source: dailypolitical.com · themarketsdaily.com
Jack Kaye is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
